Advertisement

Topics

Clinical Trials About "Prednisone Vincristine Daunorubicin Asparaginase Cyclophosphamide Methotrexate Cytosine Arabinoside" RSS

09:52 EST 16th December 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Prednisone Vincristine Daunorubicin Asparaginase Cyclophosphamide Methotrexate Cytosine Arabinoside" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Prednisone Vincristine Daunorubicin Asparaginase Cyclophosphamide Methotrexate Cytosine Arabinoside" on BioPortfolio

We have published hundreds of Prednisone Vincristine Daunorubicin Asparaginase Cyclophosphamide Methotrexate Cytosine Arabinoside news stories on BioPortfolio along with dozens of Prednisone Vincristine Daunorubicin Asparaginase Cyclophosphamide Methotrexate Cytosine Arabinoside Clinical Trials and PubMed Articles about Prednisone Vincristine Daunorubicin Asparaginase Cyclophosphamide Methotrexate Cytosine Arabinoside for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Prednisone Vincristine Daunorubicin Asparaginase Cyclophosphamide Methotrexate Cytosine Arabinoside Companies in our database. You can also find out about relevant Prednisone Vincristine Daunorubicin Asparaginase Cyclophosphamide Methotrexate Cytosine Arabinoside Drugs and Medications on this site too.

Showing "Prednisone Vincristine Daunorubicin Asparaginase Cyclophosphamide Methotrexate Cytosine Arabinoside" Clinical Trials 1–25 of 3,100+

Extremely Relevant

LAL-BR/2001: Study Treatment to Low Risk ALL

The purpose of this study is increase the efficacy of consolidation (C1) after an intensification phase with high dose of methotrexate, applying analysis of minimal residual disease


LBL-2016 for Children or Adolescents in China

The outcomes of children with lymphoblastic lymphoma (LBL) in China in our previous study were not unexpected. In this study, through further modification treatment protocols and strengthen domestic multicenter collaboration, we try to improve survival for children with LBL when compared to our previous study.

LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia

The study objective is to improve the global results obtained with LAL-AR-93 study, reaching an event free survival between 60-70%. Identify patients with bad prognosis, with minimal residual disease,who can benefit of allogenic bone marrow transplantation


LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Due to ALL Ph+ patients should receive a different treatment, is proposed a therapeutical protocol with: intensification treatment of induction to increment the CR rate, allogenic transplantation in first CR, autologous transplantation follow by alfa interferon in patients cannot done allogenic transplantation.

Intensified Post Remission Therapy Containing PEG-Asparaginase

This study is for patients with recently diagnosed blood cancer, called acute lymphoblastic leukemia (ALL). The standard treatment for this disease consists of many chemotherapy drugs that are given in different combinations in several steps. Each step of treatment is called a cycle. Patients will be treated with the chemotherapy drugs that are routinely used in ALL and which are given in multiple treatment cycles over several months. All the chemotherapy drugs that are used...

Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

The primary objective of this study (TOTXVI) is to compare the clinical benefit, the pharmacokinetics, and the pharmacodynamics of polyethylene glycol-conjugated (PEG) asparaginase given in higher dose (HD PEG) versus those of PEG-asparaginase given in conventional dose (CD PEG) during the continuation phase.

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

This is a comprehensive TOTAL therapy study of ALL, including multiple primary and secondary objectives. The primary hypotheses are to determine if central nervous system (CNS) irradiation can be safely omitted in the treatment of children with ALL, and to find out in an upfront treatment window whether prolonged (24 hour) infusion of methotrexate or short (4 hour) infusion produces greater antileukemic effects.

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

This is a Phase I study with the goals of determining the feasibility, safety, and toxicity of administering sertraline in combination with timed-sequential cytosine arabinoside (ara-C) in adults with relapsed and refractory acute myeloid leukemia. Primary objective: - To define the maximum tolerated dose (MTD) and Recommended Phase II Dose (RP2D) of sertraline administered in combination with timed-sequential cytosine arabinoside in adult patients with rel...

Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

The main purpose of this study is to find out if radiation to the central nervous system (CNS) can be safely omitted with early intensification of chemotherapy and chemotherapy given directly to the CNS. Another purpose is to find out if survival of children with ALL can be improved with risk-directed therapy given on this protocol.

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three patients to complete a 28 day cycle in the cohort, before the second three patients start treatment.

Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma

The goals of this protocol are to determine the effect of oxaliplatin, cytosine arabinoside, and dexamethasone with Rituxan (ROAD) as treatment for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL).

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

The purpose of this study is to investigate the clinical efficacy of high-dose methotrexate consolidation therapy for adult patients with BCR-ABL-negative ALL.

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Current therapeutic protocols for adult ALL consider MRD together with the baseline risk factors (age, WBC count, immunophenotype, cytogenetics) and speed in response to therapy for treatment decisions. On the other hand, the systematic use of allogeneic SCT for all adult patients (pts) with Ph- HR-ALL is still a matter of debate. The aim of the prospective study ALL-AR-03 from the Spanish PETHEMA Group was to evaluate the response to a differentiated therapy (chemotherapy or a...

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

Objectives: A. Primary objective: 1 To assess the feasibility and the effectiveness of pediatric type therapy (augmented BFM) in patients age 12 through 40 with untreated precursor-B or T acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). B Secondary 1. To evaluate the prognostic significance of minimal residual disease in bone marrow samples at the end of induction and at the end of consolidation in this group of patients...

Study for Treatment of Cancer in Children With Ataxia-Telangiectasia

This is a pilot/feasibility study designed to investigate the feasibility of treating children with Ataxia-Telangiectasia (A-T) and cancer with regimens nearly as intense as non-A-T patients with cancer would receive.

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride with asparaginase work in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing,...

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia. PURPOSE: Thisphase III trial is studying several different combination chemotherapy regimens to...

Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have untreated acute lymphoblastic leukemia.

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase III trial to study the effectiveness of combination chemotherapy in treating children who have non-Hodgkin's lymphoma.

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

RATIONALE: Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying dexamethasone to see how well it works compared to...

Trial of Alisertib With Induction Chemotherapy in High-risk AML

This research study is studying a targeted therapy (a form of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells) as a possible treatment for high-risk acute myeloid leukemia. The names of the study interventions involved in this study are: - Alisertib / MLN8237 - Cytarabine / Cytosine Arabinoside - Idarubicin / Idarubicin hydrochloride - Daunorubicin (Can be used in pla...

PONATINIB WITH CHEMOTHERAPY FOR YOUNGADULTS Ph POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Evaluate the response (complete hematologic response [CHR], complete cytogenetic response [CCyR], major molecular response [MMR] and complete molecular response [CMR] of the combination of ponatinib with standard chemotherapy (according to PETHEMA ALL Ph08 trial) in young patients with Ph+ (BCR-ABL) ALL. All patients are treated with: Pre-phase (maximum 7 days, -7 to -1): Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT) (Metho...

Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

The purpose of the study is to compare safety and efficacy of stem cell mobilization using G-CSF (filgrastim) alone vs. intermediate-dose cytosine arabinoside plus G-CSF in Hodgkin's lymphoma and non-Hodgkin's lymphoma patients.

A Study in Adults With Untreated Acute Lymphoblastic Leukemia

The purpose of this study is to determine the safety and optimal dosing of L-asparaginase in adult patients with acute lymphoblastic leukemia (ALL) between the ages of 18 and 50 years.

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

To evaluate the outcome of a prednisolone and low dose methotrexate based protocol in Down syndrome children with ALL (DS-ALL) in an Asia-wide study. The treatment protocol was modified based upon backbone of Taiwan Pediatric Oncology Group (TPOG)-ALL protocol in which risk classification will be guided by level of flow minimal residual disease (MRD) instead.


More From BioPortfolio on "Prednisone Vincristine Daunorubicin Asparaginase Cyclophosphamide Methotrexate Cytosine Arabinoside"

Advertisement
Quick Search
Advertisement
Advertisement